目录产品 » EMAP-II/AIMP1, His, Human
Manual
SDS
COAs

EMAP-II/AIMP1, His, Human

The potent antiangiogenic and proinflammatory protein Endothelial Monocyte Activating Polypeptide II (EMAP II) has been described as a mediator of pulmonary vascular and alveolar formation and its expression is inversely related to the periods of vascularization and alveolarization in the developing lung. Hence the study of EMAP II could play a vital role in studying and devising appropriate therapeutics for diseases of aberrant lung development, such as BPD.
￥2600
Z05236-100

产品简介
Species Human
Protein Construction
His EMAP-II/AIMP1 (Ala2-Lys312)_x000D_
Accession # Q12904-1
N-term C-term
Purity > 95% as determined by Bis-Tris PAGE
Endotoxin Level Less than 1EU per μg by the LAL method.
Biological Activity Measured by its binding ability in a functional ELISA. Test result was comparable to standard batch.
Expression System E.coli
Theoretical Molecular Weight 35.4 kDa
Apparent Molecular Weight The protein migrates to 40-45 kDa based on Bis-Tris PAGE result.
Formulation Supplied as 0.22μm filtered solution in 20mM Tris, 500mM NaCl, 10% Glycerol (pH 8.0).
Concentration Verified by one or more methods from 0.64mg/ml A280/Bioactivity/BCA/Bradford.
Storage & Stability This product remains stable for 6 months at -80°C or below. Avoid repeated freeze-thaw cycles.
返回

技术背景
Target Background The potent antiangiogenic and proinflammatory protein Endothelial Monocyte Activating Polypeptide II (EMAP II) has been described as a mediator of pulmonary vascular and alveolar formation and its expression is inversely related to the periods of vascularization and alveolarization in the developing lung. Hence the study of EMAP II could play a vital role in studying and devising appropriate therapeutics for diseases of aberrant lung development, such as BPD.
Synonyms EMAP-2; EMAP-II; AIMP1; HLD3; SCYE1; p43
返回

For research use only. Not intended for human or animal clinical trials, therapeutic or diagnostic use.